Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of either sex, including children over 6 years
- Chronic obstructive respiratory tract disease. Every doctor was asked to include in this study the first patients coming after each other, who were treated for the first time with Berodual® metered dose inhaler (MDI)
Exclusion Criteria:
- Contraindications listed in the Instructions for Use/Summary of Product Characteristics of Berodual® metered-dose inhaler
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
chronic obstructive respiratory tract disease patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall severity of the clinical picture rated on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with adverse drug reactions
Time Frame: up to 6 weeks
|
up to 6 weeks
|
|
Changes in dyspnea and/or asthma attacks rated on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
|
Number of dyspnea episodes rated on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
|
Number of awakenings due to night-time dyspnea rated on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
|
Assessment of morning coughing with expectoration rated on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
|
Assessment of tolerability on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
|
Changes in pathological auscultation findings rated on a 3-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
|
Changes in concomitant medication
Time Frame: up to 6 weeks
|
up to 6 weeks
|
|
Assessment of efficacy on a 4-point scale
Time Frame: after 3 and 6 weeks
|
after 3 and 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 215.1353
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.